According to the trial's crossover design, patients with refractory chronic cough of at least eight weeks» duration were randomly assigned initially to either AF - 219 or
placebo treatment twice daily for two weeks, followed by a washout period, and further followed by crossover to the alternative treatment arm (AF - 219 or placebo) for an additional two weeks.
Seventy - four patients with type - 2 diabetes were randomized to either
placebo (n = 19); or active
treatment in various doses of 600 mg once daily (n = 19),
twice daily (1200 mg; n = 18), or thrice daily (1800 mg; n = 18) alpha - lipoic acid.